Lyme Disease Testing Market Growth Outlook Indicating Expansion To $16.46 Billion By 2030

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Lyme Disease Testing Market During The 2026–2030 Period?

The lyme disease testing market has experienced substantial growth in recent years. It is anticipated to expand from $10.68 billion in 2025 to $11.67 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.3%. This historic expansion has been driven by factors such as the rising incidence of lyme disease, limited awareness regarding early diagnosis, reliance on conventional serological testing, increasing hospital-based diagnostics, and growing research in tick-borne diseases.

The lyme disease testing market size is projected to experience robust expansion over the coming years. It will grow to $16.46 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. This anticipated growth during the forecast period is due to factors such as the embrace of AI-assisted diagnostic tools, an increase in the availability of home-testing kits, the development of multi-disease panels, enhanced government financial support for monitoring tick-borne diseases, and the incorporation of cloud-based laboratory data management systems. Key developments expected throughout this period encompass the broadening of point-of-care testing, the rise of home-based lyme disease diagnostics, the introduction of multi-pathogen panels for tick-borne illnesses, the wider use of rapid test kits, and the implementation of customized diagnostic procedures.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25817&type=smp

What Important Drivers Are Powering The Lyme Disease Testing Market Growth?

The increasing occurrence of tick-borne illnesses is anticipated to boost the expansion of the lyme disease testing market in the future. These illnesses encompass various conditions passed to people via bites from contaminated ticks, which are tiny, blood-sucking parasites inhabiting grassy, forested, or countryside environments. An increasing need for treatments for tick-borne illnesses stems from ticks’ broadening geographical distribution due to climate change, resulting in increased exposure and infection levels. As the main way Lyme disease is transmitted, tick-borne illnesses drive the need for Lyme disease testing, making early identification and diagnosis crucial for managing the growing number of infections efficiently. For example, the U.S. Centers for Disease Control and Prevention (CDC), a federal public health agency based in the U.S., indicated in March 2025 that more than 89,000 Lyme disease cases were reported in 2023, showing a persistently high impact from tick-borne illnesses compared to prior years. Consequently, the growing frequency of tick-borne illnesses is stimulating the expansion of the lyme disease testing market.

Which Segment Divisions Form The Structure Of The Lyme Disease Testing Market?

The lyme disease testing market covered in this report is segmented –

1) By Test Type: Serological Tests, Nucleic Acid Tests, Urine Antigen Tests, Other Test Types

2) By Testing Methodology: Enzyme-Linked Immunosorbent Assay (ELISA), Weste Blot, Polymerase Chain Reaction (PCR), Immunofluorescence Assay (IFA), Other Emerging Technologies

3) By Disease Stage: Early Lyme Disease, Disseminated Lyme Disease, Chronic Lyme Disease, Asymptomatic Lyme Disease Detection

4) By Sample Type: Blood, Urine, Cerebrospinal Fluid(CSF), Other Blood Samples

5) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Home Care Settings, Research Institutions, Public Health Organizations

Subsegments:

1) By Serological Tests: Enzyme-Linked Immunosorbent Assay, Western Blot, Immunofluorescence Assay (IFA), Line Immunoassay (LIA)

2) By Nucleic Acid Tests: Polymerase Chain Reaction (PCR), Loop-Mediated Isothermal Amplification (LAMP), Next-Generation Sequencing (NGS)

3) By Urine Antigen Tests: Lateral Flow Assay, Enzyme Immunoassay (EIA), Immunoblot Urine Tests

4) By Other Test Types: Culture-Based Tests, Tick-Borne Co-Infection Panels, Artificial Intelligence-Assisted Diagnostic Tools

What Trends Are Affecting The Growth Of The Lyme Disease Testing Market?

Companies operating in the Lyme disease testing market are increasingly concentrating on technological improvements in diagnostic instruments to boost test precision, decrease processing times, and facilitate the early identification of the condition. Diagnostic tools refer to medical equipment, kits, or technologies utilized to confirm the presence of Lyme disease by identifying distinct antibodies, antigens, or genetic material linked to the Borrelia burgdorferi bacteria. For instance, in August 2024, EpitogenX Ltd., a UK-based biotechnology company, revealed the launch of a sophisticated Lyme Disease Diagnostic Kit. This kit is an ELISA-based assay engineered using their proprietary EpitoGen platform. It incorporates ~120 distinct Borrelia epitopes, offering high specificity and sensitivity, and is specifically designed for research use (RUO). It supports early, strain-specific detection and can be customized for various laboratory applications. Created for both research and diagnostic labs, it is optimal for enhancing detection accuracy and enabling deeper insights into Lyme disease.

Which Firms Are Competing In The Lyme Disease Testing Market?

Major companies operating in the lyme disease testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific, BIOMÉRIEUX, Quidel Corporation, Bio Rad Laboratories Inc., QIAGEN N.V., DiaSorin S.p.A, Meridian Bioscience, Trinity Biotech, T2 Biosystems, IGeneX, Viramed Biotech AG, Ceres Nanosciences, Galaxy Diagnostics, Lyme Diagnostics Ltd, Abbott Laboratories, Siemens Healthineers AG, Hologic Inc., Seegene Inc.

Access The Complete Lyme Disease Testing Market Report:

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Which Region Leads The Lyme Disease Testing Market By Size?

North America was the largest region in the lyme disease testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Lyme Disease Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/report/lyme-disease-testing-global-market-report

Browse Through More Reports Similar to the Global Lyme Disease Testing Market 2026, By The Business Research Company

Biologics Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-testing-global-market-report

Covid 19 Saliva Screening Test Potential Market Report 2026

https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report

Typhoid Antibody Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/typhoid-antibody-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795